

Technology Advisory Interests Register

Topic: Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable [ID3887]

Publication Date: 26 March 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Pedro Saramago Goncalves	Committee Member	Financial Interests	Dr Goncalves has carried out health economics work in an advisory capacity for Accord healthcare (with a potential comparator treatment for this appraisal) on an unrelated disease area (lung cancer).	10/09/2024 14/01/2024	It was agreed that Dr Goncalves declaration would not prevent him from participating in discussions on this appraisal.
Elizabeth Thurgar	Committee Member	Financial Interests	In the past 12 months, Elizabeth has provided consultancy advice to BMS in an unrelated indication which was myelodysplastic syndrome. In addition to this, she is currently working with Pfizer, a listed comparator company, in an unrelated indication, non-small cell lung cancer.	10/09/2024	It was agreed that Elizabeth Thurgars' declaration would not prevent her from participating in discussions on this appraisal.
Michael Chambers	Committee Member	Financial Interests	Michael has participated in an advisory panel for Pfizer, a listed comparator company, in an unrelated disease area: prostate cancer.	10/09/2024 14/01/2024	It was agreed that Michael Chambers declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Kate Ren	Committee Member	Financial Interests	Dr Ren provided statistical methodology consultancy service for Pfizer, a listed comparator company, for an unrelated treatment in an unrelated disease area: Tofacitinib for Moderate-to-Severe Ulcerative Colitis.	16/09/2024 14/01/2024	It was agreed that Dr Rens declaration would not prevent her from participating in discussions on this appraisal.
Satish Venkateshan	Committee Member	Financial Interests	Satish works for, and has shares and stock options in, Regeneron, a pharmaceuticals/biotech company. Regeneron is developing Odronextamab CD20xCD3 bispecific antibody for certain B cell lymphomas and has recently been approved by EMA for certain relapsed/refractory (R/R) follicular lymphoma (FL) or certain R/R diffuse large B-cell lymphoma (DLBCL).	16/09/2024	It was agreed Satish Venkatesan's declaration would prevent him from participating in discussions on this appraisal.
Stella O'Brien	Committee Member	Non-Financial Professional Interests	Stella is a member of the Genetics Alliance UK PPIE Working Group on ATMPs affiliated with CATAPULT cell and gene therapy to encourage the integration of PPIE throughout the research cycle from the earliest stages and onwards. CATAPULT is a network of not-for profit, independent centres which connect businesses with the UK's research and academic communities.	20/09/2024 14/01/2024	It was agreed that Stella O'Brien's declaration would not prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Prof. Stephen O'Brien	Committee Member	Non-Financial Professional Interests	Prof. O'Brien is a friend and colleague of clinical expert Dr Wendy Osborne.	02/10/2024 14/01/2024	It was agreed that Prof. O'Brien's declaration would not prevent him from participating in discussions on this appraisal.
Clare Offer	Committee Member	Non-Financial Professional Interests	Clare sits on the NHS England national Clinical Reference Group for Blood and Marrow Transplant (BMT) as a public health expert. This includes some review of general CAR-T service specifications. She was not involved with policy developments relating to this treatment.	12/12/2024	It was agreed that Clare Offer's declaration would not prevent her from participating in discussions on this appraisal.
Christopher Fox	Clinical Expert	Financial Interests	Christopher has received consultancy fees from BMS for advisory boards, some of which relate directly to the technology being appraised. He has also received speaker honoraria and consultancy fees relating to the same disease area from Roche.	25/03/2024 14/01/2024	It was agreed that Christopher Fox's declaration would not prevent him from participating in discussions on this appraisal.
Wendy Osbourne	Clinical Expert	Financial Interests	Wendy has received consultancy fees for advisory boards and speaker fees from BMS. She has also received support for study leave, speaker fees and fees for	25/03/2024 14/01/2024	It was agreed that Wendy Osbourne's declaration would not prevent her from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			advisory boards from BMS, Pfizer and Roche.		
Christopher Strange	Patient Expert	Financial Interests	Christophers nominating organisation Blood Cancer UK has received funding from BMS	03/06/2024 14/01/2024	It was agreed that Christopher Strange's declaration would not prevent him from participating in discussions on this appraisal.